Recent advances in pulmonary hypertension therapy

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 1, 2008, Pages 28-36

  Ramakrishna, Harish ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adenosine monophosphate; AMP; Cardiac index; CI; GMP; Guanosine monophosphate; Mean pulmonary artery pressure; MPAP; Nitric oxide; Nitric oxide synthase; NO; NOS; PAH; PAP; PCWP; PH; PPH; Primary pulmonary hypertension; Pulmonary artery hypertension; Pulmonary artery pressure; Pulmonary capillary wedge pressure; Pulmonary hypertension; Pulmonary vascular resistance; PVR; SNP; Sodium nitroprusside; Stroke volume index; SVI; SVR; Systemic vascular resistance; V Q; Ventilation perfusion

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LEVOSIMENDAN; LIPOXYGENASE INHIBITOR; MILRINONE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; OXYGEN; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; SILDENAFIL; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN;

AMNESIA; ANALGESIA; ANESTHESIST; ASCITES; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIUM; GENERAL ANESTHESIA; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HUMAN; LOADING DRUG DOSE; LUNG BLOOD VESSEL; LUNG EDEMA; METHEMOGLOBINEMIA; MORBIDITY; MORTALITY; MUSCLE RELAXATION; NERVE BLOCK; NONHUMAN; OPERATING ROOM; PERIOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ADMINISTRATION, INHALATION; ANIMALS; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; INTRAOPERATIVE COMPLICATIONS; NITRIC OXIDE; PATENTS AS TOPIC; PULMONARY CIRCULATION; VASODILATOR AGENTS;

EID: 38949131227     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008783331616     Document Type: Review

References (40)

1. D'Alonzo GE, Barst RJ, Ayres SK et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
2. AACP Guidelines. Chest 2004; 126.
3. Murad F. The Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate: JAMA 1996; 276: 1189-1192.
4. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Inter Med 1994; 120: 227-237.
5. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002; 99: 8306-8311.
6. Weiss B, Hait WN. Selective cyclic nocleotide phosphodiesterase inhibitors as potential therapeutic agents. Ann Rev Pharmacol Toxicol 1977; 17: 441-477.
7. Takimoto E, Champion HC, Li K et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222.
8. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-1540.
9. Mills RM, LeJemel TH, Hoston DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am College Cardiol 1999; 34: 155-162.
10. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995; 75:3A-10A.
11. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96:2782-2784.
12. Haslam RJ, McClenaghan MD. Measurement of circulating prostacyclin. Nature 1981; 292: 364-366.
13. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-606.
14. Sandell EP, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovas Pharmacol 1995; 26 Suppl 1: S57-62.
15. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am College Cardiol 2000; 36: 1903-1912.
16. Figgitt DP, Gillies PS, Goa K.L. Levosimendan. Drugs 2001; 61: 613-627; discussion 628-619.
17. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999; 91: 1090-1121.
18. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology 2003; 99: 1415-1432.
19. Ichinose F, Roberts JD, Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004; 109: 3106-3111.
20. Haddad E, Millatt L, Johns R. Clinical applications of inhaled NO. In: Kadowitz P, ed. Lung Physiology. New York: Marcel Dekker, 2000.
21. Schutte H, Grimminger F, Otterbein J, et al. Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation. J Pharmacol Exper Therapeut 1997; 282: 985-994.
22. Meadow W, Rudinsky B, Bell A, Hipps R. Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. Pediat Res 1998; 44: 181-186.
23. Gong F, Shiraishi H, Kikuchi Y, et al. Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619. Pediatr Int 2000; 42: 255-258.
24. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93: 1439-1445, table of contents.
25. Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Canad J Anaesth 2005; 52: 1076-1082.
26. Denault AY, Lamarche Y, Couture P, et al. Inhaled milrinone. a new alternative in cardiac surgery? Semin Cardiothor Vasc Anesth 2006; 10: 346-360.
27. Szczeklik A, Gryglewski N, Nizankowska E, Nizankowski R, Musial J. Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins 1978; 16: 651-660.
28. Shimokawa H, Flavahan NA, Lorenz RR, Vanhoutte PM. Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br J Pharmacol 1988; 95: 1197-1203.
29. Wen V, Watanabe K, Yoshida M. Nitric oxide enhances PGI(2)production by human pulmonary artery smooth muscle cells. Prostagglandins Leuko Essent Fatty Acids 2000; 62: 369-378.
30. Mikhail G, Gibbs J, Richardson K et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997; 18: 1499-1504.
31. Hill LL, Pearl RG. Combined inhaled nuric oxide and inhaled. prostacyclin during experimental chronic pulmonary hypertension. J Appl. Physiol 1999; 86: 1160-1164.
32. Della Rocca G, Coccia C, Costa MG, et al. Inhaled areosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. Transplant Proc 2001; 33: 1634-1636.
33. Miller OI, Tang SF, Keech A Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346: 51-52.
34. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992; 43: 889-924.
35. Zisman, L.S.: WO07101232 (2007).
36. Maitland M.G., Ratain. M.: WO07087575 (2007).
37. Ahker, S., Springer, J,: WO07014586 (2007).
38. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL, Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000; 117: 819-827.
39. Block, L.Z.: EPI 792915 (2007).
40. Fong, B.: WO07050783 (2007).